@dansfera: The mental health market is clearly exploding post-COVID, and the commercial viability for novel in-clinic treatments is already proven. That \$689 million revenue haul by Janssen’s intranasal esketamine in 2023 is a massive validation! It shows robust safety protocols don't block broad payer acceptance or huge commercial success. Intrigued to see how the Phase II top-line results stack up against that benchmark. Big moves happening in this space! #MentalHealth #PharmaInvesting #NovelTherapy #MarketValidation #HealthcareInnovation